Despite individual regulatory bodies having their own unique set of requirements, for most organisations, the challenges associated with annual product quality reviews (APQR) are largely the same. Issues with fragmented systems and paper-based processes prove increasingly burdensome.
Jazz Pharmaceuticals licences KRAS blocker from Redx Pharma
Latest NewsJazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.
Spanish plant-based protein producer Heüra Foods closes Series B financing
Latest NewsSpanish Food tech Start-up Heüra Foods secures €40m in Series B financing round to expand product distribution.
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN
Latest NewsBiovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN.
OneChain Immunotherapeutics with new CEO
AppointmentsStefanos Theoharis joins OneChain Immunotherapeutics (OCI) as new CEO. He follows Jorge Alemany, CEO since 2022, when the Spin-off from the Josep Carreras Leukemia Research Institute has started.
The Best Strategies to Modernise Pharmaceutical Quality Systems
Sponsored PublicationsDespite individual regulatory bodies having their own unique set of requirements, for most organisations, the challenges associated with annual product quality reviews (APQR) are largely the same. Issues with fragmented systems and paper-based processes prove increasingly burdensome.
Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics
Latest NewsTo improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of mRNA products
Abionyx Pharma with new CMO and Head of R&D
AppointmentsDr Rob Scott, former Chief Medical Officer and Head of Development at AbbVie, joined Abionyx Pharma in January as new CMO and Head of Research and Development.
£26m for Cystic Fibrosis Drug Trial
Latest NewsEnterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.
Alvotech Advances in Biosimilar Market with Successful AVT03 Study
Latest NewsAVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.
Novozymes and Chr. Hansen Complete Merger, Forming Novonesis
Latest NewsDanish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, creating a new company named Novonesis.